TOHO HOLDINGS CO., LTD. Announces Capital Alliance with HekaBio K.K.

March 19, 2018


Company Name: TOHO HOLDINGS CO., LTD.

Corporate Representative: Norio Hamada,

             Chairman of the Board and Representative Director

(First Section of Tokyo Stock Exchange Securities Code:8129)

Contact: Makoto Kawamura, Corporate Officer, General Manager,

Public and Investor Relations Department (TEL: 81-3-6838-2803)


Announcement about Capital Alliance with HekaBio K.K.

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Chairman of the Board and Representative Director: Norio Hamada; hereinafter, “TOHO HOLDINGS”) announces today it has decided to subscribe to the third-party share issuance by HekaBio K.K. (Headquarters: Tokyo; CEO: Robert Evans Claar; hereinafter, “HekaBio"), a bio venture company. Specifics are as outlined below:

1. Reason for capital alliance

TOHO HOLDINGS is a corporate group active in medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan "Total Commitment to Good Health". TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

HekaBio endeavors to contribute to the advancement of medical care by introducing innovative, novel therapeutics from overseas for patients fighting intractable cancer and autoimmune/inflammatory disease. HekaBio’s leadership conducts businesses based on experience from previously established Japan-based companies including Junicon K.K. (est. 1992), a healthcare market research consulting firm for Japanese, American and European companies, and Vorpal Technologies K.K. (est. 2013), a medical device and pharmaceutical CRO.

TOHO HOLDINGS and HekaBio share the same philosophy of contribution to society and medical care. Through this investment, TOHO HOLDINGS will collaborate in the development, marketing and distribution of new and innovative therapeutics in Japan.

2. Overview of HekaBio K.K.

(1) Company name: HekaBio K.K.

(2) Location: Yashima Bldg 3F, 2-7-14 Toranomon, Minato-ku, Tokyo

(3) Representative: Robert Evans Claar, CEO

(4) Established: November 2016 (Company name changed to HekaBio K.K. in November 2017)

(5) Business content: Import, development, manufacturing and sales of pharmaceutical,

medical device, diagnostic and regenerative medicine products

(6) Capital: JPY 94.514 million

(7) Fiscal year end: December 31

(8) Number of employees: 7

(9) Contact: Ben Pratt, COO (TEL: 81-3-6205-7585, email: ben.pratt@hekabio.com)

3. Number of shares, method, price, shares owned before and after acquisition and share acquisition date

(1) Number of shares to be acquired: 1,400 Class A shares

(2) Acquisition method: Subscription to third-party allotment of shares issued by HekaBio

(3) Acquisition price: Undisclosed

(4) Shares owned prior to acquisition: 0 (Ownership percentage: 0%)

(5) Shares owned after acquisition: 1,400 (Fully diluted ownership percentage: 6%)

(6) Date of share acquisition: March 20, 2018

4. Forward looking outlook

Impact to consolidated performance is minor.

最新記事

すべて表示

AlphaTau Medical LtdとHealthcare Capital Corp.が合併し、アルファ粒子線照射による固形腫瘍の治療に焦点を当てた10億ドル規模の上場企業を設立

ヘカバイオ株式会社のパートナー企業であるAlpha Tau Medical Ltd は7月9日(現地時間7月8日)に、Special Purpose Acquisition Company(特別買収目的会社)であるHealthcare Capital Corp.(Nasdaq:HCCC)と共に上場企業を設立し、2021年末にかけてNasdaqへ上場すると発表しました。 両社によるプレスリリースはこ

ポリープ状脈絡膜血管症(加齢黄斑変性症の一種)の先進的治療を開発するSalutarisMD社とライセンス契約を締結

ヘカバイオ株式会社(以下、ヘカバイオ)は、加齢黄斑変性症の中でもアジア人に多いポリープ状脈絡膜血管症(PCV)の治療のため開発されたBetaCurveの日本におけるライセンスおよび商業化の契約をSalutaris Medical Devices Inc.(以下SalutarisMD社)と締結しました。 同社が開発したBetaCurveは、Sr90(ストロンチウム90:放射性同位元素)を用いたβ線を

新株発行により4億円の資金調達を達成

ヘカバイオ株式会社(東京都中央区日本橋本石町3-3-16)は2021年1月29日付にて4億円の第三者割当増資を行いました。 今回の増資により調達した資金は、今後当社が開発を手掛けるポートフォリオを拡充させるために活用いたします。 当社は、人々の医療と健康への貢献を使命として、世界への窓口として日本にベースに置き、海外の製品の導入に特化して開発や市場化を行っています。がん、線維性疾患、自己免疫性炎症